MonTa Biosciences have completed our regulatory meeting with the Danish Medicines Agency to align views on development strategy and interpretation of ICH guidelines. MonTas plan for moving our lead candidate MBS8 into the clinic was well supported, securing a clear path forward toward, and a smooth process for our Clinical Trial Application filed in the near future. Thanks to our consultants Ozack and Ingrid Bøgh for great help in the process.
